Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

OTLK vs CCCC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OTLK Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–5 Matrix Metrics)

OTLK Overall Winner 6-Pillar Tally: OTLK 4 – 1 CCCC (1 Tie) Matrix Metrics: OTLK 5 – 5 CCCC

As of Nov 16, 2026, Outlook Therapeutics, Inc. (OTLK) is the stronger overall head-to-head candidate over C4 Therapeutics, Inc. (CCCC) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). OTLK carries a Unified Composite Score of 48.6/100 (HOLD) at $0.40 (2.9x Forward P/E, 4781.8% operating margin), whereas CCCC carries 55.0/100 (HOLD) at $2.69 (N/M Forward P/E, -315.9% operating margin).

  • Composite vs. Pillar Nuance: While CCCC currently prints a higher short-term Unified Composite Score (55.0/100 HOLD vs. OTLK 48.6/100 HOLD), OTLK captures the overall institutional head-to-head verdict (5–5 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (4781.8% vs. -315.9% operating margin) and revenue trajectory (-99.4% vs. -24.6% YoY).
  • Technical & Structure Timing Caution: OTLK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.2); meanwhile CCCC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OTLK vs CCCC
OTLK NASDAQ Head-to-Head Winner
Outlook Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.40
-4.04% 1D
Market Cap $107.1M
TTM Revenue N/A
Forward P/E 2.9x
Beta / 30D Vol 1.47β · 79% Vol
Unified Composite Score
48.6 / 100 HOLD
Tech 33.0 Fund 48.0 Flow 71.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.5%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $0.48 · SMA50: $0.56
CCCC NASDAQ
C4 Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$2.69
-2.72% 1D
Market Cap $363.7M
TTM Revenue $32M
Forward P/E N/M
Beta / 30D Vol 1.43β · 67% Vol
Unified Composite Score
55.0 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.4%), weak momentum, RSI 38
RSI-14: 38.0 · SMA20: $3.08 · SMA50: $3.11

6-Pillar Scorecard Institutional Category Breakdown (OTLK 4 – 1 CCCC)

Columns: Metric · OTLK · CCCC
1. Valuation Multiples OTLK
Forward P/E 2.9x N/M
Trailing P/E 2.9x N/M
PEG Ratio N/M N/M
EV / Revenue N/M 12.0x
2. Growth & Scale CCCC
Revenue Growth (YoY) -99.4% -24.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $32M
Market Cap $107.1M $363.7M
3. Profitability & Quality OTLK
Gross Margin N/A 88.8%
Operating Margin 4781.8% -315.9%
Net Profit Margin 0.0% -282.2%
Return on Equity (ROE) -3.6% -47.6%
4. Balance Sheet & Cash Flow OTLK
Cash Generation (TTM) -$56M -$80M
Cash Flow Margin N/A N/A
Net Cash / Leverage $7.2M Net Debt $23M Net Debt (0.24x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OTLK
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 181.3% (55th %ile) 79.8% (3rd %ile)
Put/Call OI Skew 0.26x (Call-Skewed) 0.09x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OTLK (5) vs CCCC (5)
Institutional Metric OTLK CCCC Criterion Row Edge
Market Capitalization
Scale
$107.1M $363.7M Larger Scale CCCC
Trailing P/E Ratio
Valuation
2.9x N/M Lower Multiple OTLK
Forward P/E Ratio
Valuation
2.9x N/M Lower Multiple OTLK
Revenue Growth (YoY)
Growth
-99.4% -24.6% Higher Growth CCCC
Operating Margin (TTM)
Profitability
4781.8% -315.9% Higher Margin OTLK
Net Profit Margin
Profitability
0.0% -282.2% Higher Margin OTLK
Return on Equity (ROE)
Capital Efficiency
-3.6% -47.6% Higher ROE OTLK
52-Week Range Position
Momentum
10% ($0–$3) 29% ($2–$5) Stronger Trend CCCC
Beta / 30D Volatility
Risk Regime
1.47β · 79% Vol 1.43β · 67% Vol Lower Realized Risk CCCC
Unified Institutional Score
Composite Signal
48.6 / 100 (HOLD) 55.0 / 100 (HOLD) Higher Composite CCCC
Trailing 12M Revenue (USD)
Operating Scale
N/A $32M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 88.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 12.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$56M ($7.2M Net Debt) -$80M ($23M Net Debt (0.24x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CCCC +15.93 pp
OTLK: -18.82% · CCCC: -2.89%
3M Horizon CCCC +7.62 pp
OTLK: -43.39% · CCCC: -35.77%
6M Horizon OTLK +89.52 pp
OTLK: +72.91% · CCCC: -16.61%
1Y Horizon CCCC +82.63 pp
OTLK: -73.04% · CCCC: +9.59%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period OTLK Revenue CCCC Revenue OTLK Op. Margin CCCC Op. Margin Margin Leader
FY2017 $0M N/A -941.4% N/A OTLK
FY2018 $0M N/A -960.1% N/A OTLK
FY2019 $10M N/A -445.6% N/A OTLK
FY2021 N/A $50M N/A -179.4% CCCC
FY2022 N/A $30M N/A -416.6% CCCC
FY2023 N/A $20M N/A -669.8% CCCC
FY2024 N/A $40M N/A -336.1% CCCC
FY2025 $0M $40M -4744.3% -320.5% CCCC

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OTLK BREAKDOWN
103d in phase · OBV NEUTRAL
Current IV 181.3%
IV Percentile 55th %ile
Put/Call OI Skew 0.26x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact OTLK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CCCC BREAKDOWN
117d in phase · OBV DISTRIBUTION
Current IV 79.8%
IV Percentile 3rd %ile
Put/Call OI Skew 0.09x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CCCC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OTLK Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $107.1M market capitalization and 4781.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CCCC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $363.7M market capitalization and -315.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OTLK vs CCCC Key Questions & Quantitative Answers

As of Nov 16, 2026, Outlook Therapeutics, Inc. (OTLK) is the stronger overall head-to-head candidate over C4 Therapeutics, Inc. (CCCC) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). OTLK carries a Unified Composite Score of 48.6/100 (HOLD) at $0.40 (2.9x Forward P/E, 4781.8% operating margin), whereas CCCC carries 55.0/100 (HOLD) at $2.69 (N/M Forward P/E, -315.9% operating margin). Composite vs. Pillar Nuance: While CCCC currently prints a higher short-term Unified Composite Score (55.0/100 HOLD vs. OTLK 48.6/100 HOLD), OTLK captures the overall institutional head-to-head verdict (5–5 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (4781.8% vs. -315.9% operating margin) and revenue trajectory (-99.4% vs. -24.6% YoY). Technical & Structure Timing Caution: OTLK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.2); meanwhile CCCC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CCCC leads the Growth & Scale pillar: OTLK posts -99.4% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 4781.8% operating margin), compared with CCCC at -24.6% YoY revenue growth and +0.0% YoY earnings growth on $32M TTM revenue (88.8% gross margin, -315.9% operating margin). Across the 8-period historical trajectory (FY2017 to FY2025), OTLK cumulative revenue shifted N/A while CCCC shifted -20.0%. In operating R&D and SG&A reinvestment, OTLK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CCCC.

OTLK screens cheaper on headline valuation multiples. OTLK trades at 2.9x Forward P/E, 2.9x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CCCC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 12.0x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OTLK (-3.6% ROE) versus CCCC (-47.6% ROE) capital efficiency.

In options market volatility and institutional positioning, OTLK carries 181.3% implied volatility (55th %ile, Balanced (25th–60th %ile)), a 0.26x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.47β · 79% Vol realized risk). By comparison, CCCC carries 79.8% implied volatility (3rd %ile, Compressed (<25th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.43β · 67% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.